Hyperbaric Oxygen Therapy (HBOT)

Hyperbaric oxygen therapy is a clinician-supervised chamber protocol that exposes a person to high oxygen partial pressure. Longevity use targets vascular, cognitive, repair, and cellular-aging markers, not a proven lifespan endpoint.

Also known as: HBOT, HBO2 therapy, hard-chamber oxygen therapy, intermittent hyperoxic exposure

Context

Hyperbaric oxygen therapy (HBOT) is established medicine for selected indications. The basic procedure is simple to describe: the patient breathes near-100% oxygen inside a chamber pressurized above normal atmospheric pressure. The clinical reality is more specific. Pressure, oxygen concentration, session duration, air breaks, chamber type, indication, supervision, and emergency readiness define the intervention.

In ordinary hyperbaric medicine, HBOT is used for conditions such as decompression sickness, carbon monoxide poisoning, selected problem wounds, gas embolism, delayed radiation injury, compromised grafts and flaps, refractory osteomyelitis, and other indications recognized by hyperbaric-medicine authorities. Those indications do not make HBOT a general longevity treatment. They show that the procedure is real medicine with real infrastructure.

The longevity version points to the Tel Aviv / Shamir Medical Center research program associated with Shai Efrati and colleagues: 60 sessions over roughly three months, breathing 100% oxygen at 2 ATA for 90 minutes with periodic air breaks. That protocol is very different from a consumer “mild hyperbaric” chamber at lower pressure, with less oxygen delivery and less medical supervision.

The useful question isn’t “does oxygen help?” — it’s which protocol, in which chamber, for which endpoint, in which population, with which safety system.

Problem

HBOT attracts a familiar longevity error: a real clinical tool becomes a wellness category. The same phrase can refer to hospital-grade therapy for decompression sickness, a hard-chamber cognitive-aging trial, a clinic’s 60-session package, a soft inflatable chamber in a spa, or a public protocol copied from an expensive longevity program. Those are not the same intervention.

The soft-versus-hard distinction matters because pressure and oxygen partial pressure are the active variables. A lower-pressure chamber with ambient air or loose-mask oxygen delivery doesn’t reproduce a 2 ATA, 100% oxygen research protocol. The buyer may still feel something. The evidence base doesn’t transfer.

The evidence can also be overread. Telomere lengthening in isolated blood cells, improved cognitive scores in small older-adult trials, and a VO2max signal after 60 sessions are meaningful findings. They are not proof that HBOT extends human lifespan, prevents dementia in healthy adults, or belongs in a routine longevity stack.

Forces

• HBOT is established for selected medical indications, but healthy-aging and longevity uses remain off-label or investigational.
• Hard-chamber pressure, oxygen fraction, air breaks, and session count determine the biological exposure.
• Soft-chamber and “mild HBOT” offers are more accessible, but they don’t match the main aging-trial protocols.
• Human trials show cognitive, physical, and cellular-marker signals in older adults, but no long-term disease-incidence, disability, or survival outcome has been shown.
• Fire, barotrauma, oxygen toxicity, claustrophobia, pulmonary risk, seizure risk, and device-safety failures make supervision part of the intervention.
• Clinics can sell the same chamber protocol as regenerative medicine, performance enhancement, brain optimization, or healthy-aging care before the endpoint evidence is mature.

Solution

Treat HBOT as a protocol-specific clinical exposure, not as a generic oxygen wellness service. A defensible offer specifies the variables: chamber type, pressure in ATA, oxygen delivery method, session duration, air-break schedule, total session count, clinical owner, screening process, endpoint, and adverse-event plan.

For longevity-adjacent use, the minimum description should name what is being tested: cognition, cerebral blood flow, VO2max, wound healing, telomere length, senescent-cell fractions, fatigue, pain, or another endpoint. A clinic that sells “cellular regeneration” without stating the endpoint is asking mechanism language to do too much work.

The reference protocol in the healthy-aging literature uses 60 daily sessions over 12 weeks: 100% oxygen at 2 ATA, 90 minutes per session, five-minute air breaks every 20 minutes. That is a published-study protocol, not a reader instruction. A treating hyperbaric physician may reject the protocol, modify the interval, or refuse the indication entirely.

The safety file is part of the pattern, not an annex to it. It covers screening (ear and sinus, pulmonary history, seizure history, oxygen-toxicity risk, glucose handling when relevant, medication review, implanted device review), facility readiness (fire-prevention procedures, chamber maintenance, trained staff, patient monitoring), and a documented response plan for barotrauma, panic, chest symptoms, neurologic symptoms, or device malfunction.

Evidence

Evidence tier: RCT (human) for short-term cognitive and physical endpoints in small older-adult trials; observational or mechanistic for cellular-aging markers; no human lifespan or disability-free-survival evidence. The evidence stack is promising, narrow, and commercially easy to overstate.

Start with the accepted clinical foundation. Undersea and Hyperbaric Medical Society materials list recognized indications, physician prescription, qualified supervision, and repeated daily sessions over weeks. The same materials warn that low-pressure “mild hyperbaric oxygen” is unproven and is often delivered outside medical facilities.

The 2020 cognitive-aging trial randomized 63 healthy adults over 64 to HBOT or control for three months. The HBOT arm used 60 sessions at 2 ATA for 90 minutes with air breaks. The authors reported improvements in global cognitive scores, attention, information-processing speed, task switching, and cerebral blood flow measures. That is a real human RCT signal — and a small, short trial from a research group linked to a commercial HBOT program.

The 2020 telomere and immunosenescence study enrolled 35 healthy adults 64 and older and used a similar 60-session protocol. The authors reported increased telomere length and reduced senescent-cell percentages in several isolated peripheral-blood immune-cell populations. The study supports biological plausibility. It was not randomized, did not measure clinical events, and did not show that lengthening telomeres in blood cells changes lifespan or disease risk.

A 2024 randomized trial in sedentary older adults tested physical performance with the same 60-session, 2 ATA protocol. It reported a net VO2max/kg increase of about 1.9 mL/kg/min, improved oxygen consumption at the first ventilatory threshold, and cardiac-perfusion changes versus controls. The conflict-of-interest statement matters: several authors worked for AVIV Scientific, and Efrati was listed as a shareholder and co-founder. That doesn’t invalidate the data, but it raises the replication bar.

The 2025 FDA safety letter adds a practical boundary. FDA-cleared HBOT devices are Class II devices cleared through the 510(k) process, and FDA warned providers about serious injuries and deaths reported with HBOT devices, including fire events. The agency emphasized manufacturer instructions, fire prevention, staff training, patient monitoring, cleaning, maintenance, and adverse-event reporting. The chamber is a medical device, not a spa pod.

How It Plays Out

A 67-year-old sees a 60-session HBOT program marketed for cognitive aging. The useful first pass is protocol matching: is the clinic using a hard chamber, 100% oxygen, about 2 ATA, air breaks, trained staff, physician supervision, and a defined endpoint? If the answer is no, the clinic may be selling access to a chamber while borrowing evidence from another protocol.

A high-performing executive adds HBOT after hearing that it lengthens telomeres. The better interpretation is narrower: one small prospective study found blood-cell marker changes after a demanding protocol. That doesn’t mean a middle-aged adult with normal function should expect fewer heart attacks, less dementia, or longer life.

A person with chronic ear problems, lung disease, seizure history, implanted devices, or unstable cardiovascular disease asks about HBOT at a longevity clinic. The question has moved from performance to medical eligibility. Ear barotrauma, pulmonary barotrauma, oxygen-toxicity seizure, glucose shifts, anxiety inside the chamber, and fire risk are not side notes. They are why the protocol belongs under qualified supervision.

Consequences

Benefits. HBOT is more inspectable than many frontier interventions. The chamber, pressure, oxygen delivery, session count, and monitoring plan can be specified. The procedure has a legitimate clinical history, professional guidance, and small human RCTs reporting cognitive and physical-performance signals in older adults.

HBOT is also a useful contrast case for this section: it does not add stem cells, exosomes, donor plasma, or unapproved peptides. It changes the oxygen environment repeatedly, which makes the mechanism easier to study and the clinic offer easier to audit.

Liabilities. The cost is high, the time burden is large, and the evidence is endpoint-limited. A 60-session protocol can consume three months and five figures. Expensive and technical doesn’t mean settled.

The protocol can also be mismatched. A soft-chamber program may be convenient but biologically different from the cited research. A hard-chamber program may match the exposure but still lack a clear endpoint, a clinician-owned plan, or a defensible candidate rationale.

The practical rule is conservative: pay attention to pressure, oxygen delivery, endpoint, supervision, and stopping rule before paying attention to the promise. If the clinic can’t state those cleanly, the reader is seeing Medical Tourism Quality Roulette or clinic theater, not mature longevity medicine.

Related Articles

Sources

• FDA. “Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices: Letter to Health Care Providers.” August 25, 2025. https://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers
• Hachmo, Yafit, Amir Hadanny, Ramzia Abu Hamed, et al. “Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial.” Aging 12, no. 22 (2020): 22445-22456. https://www.aging-us.com/article/202188
• Hadanny, Amir, Malka Daniel-Kotovsky, Gil Suzin, et al. “Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.” Aging 12, no. 13 (2020): 13740-13761. https://pmc.ncbi.nlm.nih.gov/articles/PMC7377835/
• Hadanny, Amir, Efrat Sasson, Laurian Copel, et al. “Physical enhancement of older adults using hyperbaric oxygen: a randomized controlled trial.” BMC Geriatrics 24 (2024): 572. https://doi.org/10.1186/s12877-024-05146-3
• Undersea and Hyperbaric Medical Society. “HBO Indications.” Accessed May 10, 2026. https://www.uhms.org/resources/featured-resources/hbo-indications.html

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

HBOT is a pressure-and-oxygen medical-device intervention with risks that include ear and sinus barotrauma, pulmonary barotrauma, oxygen-toxicity seizure, hypoglycemia in susceptible patients, claustrophobia, fire, device malfunction, and complications related to unstable medical conditions. Eligibility, chamber type, pressure, oxygen delivery, session duration, air breaks, monitoring, contraindications, adverse-event handling, and stopping rules belong to a qualified clinician and an appropriately equipped hyperbaric service.